Browse Studies — Arctuva

Phase 1

A Phase 1 Adaptive Dose Escalation With Dose Expansion Study of Triapine in Combination With Temozolomide (TMZ) for Patients With Recurrent Glioblastoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with temozolomide in treating patients with glioblastoma that has c…

Recurrent Glioblastoma, IDH-WildtypeRecurrent WHO Grade 2 GliomaRecurrent WHO Grade 3 Glioma+1 more

Estimated

~$10 – $6,250

Northwestern UniversityNCT06410248

Phase 1

A Phase I, Dose-Escalation Trial of Anti-GARP Chimeric Antigen Receptor-T Cell Therapy in Patients With Recurrent High-Grade Glioma Treated at a Single Medical Center

This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell t…

Recurrent Malignant GliomaRecurrent WHO Grade 3 GliomaRecurrent WHO Grade 4 Glioma+3 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT06964737

Phase 2

A Phase II Open Label, Randomized Study Testing the Efficacy of Retifanlimab in Combination with Bevacizumab and Hypofractionated Radiotherapy in Patients with Recurrent GBM

This phase II trial tests how well retifanlimab with bevacizumab and hypofractionated radiotherapy, compared to bevacizumab and hypofractionated radiotherapy a…

Recurrent GlioblastomaRecurrent WHO Grade 4 Glioma

Estimated

~$10 – $7,500

Academic and Community Cancer Research UnitedNCT06160206